Treatment sequences of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: A nationwide population-based study in France
Authors' conclusion
In this nation-wide analysis of 26 478 patients, TNFi was the most frequently dispensed first-line b/tsDMARD, with LT modulators and IL-6i preferred in second-line therapy.
Study context
- Population
- French patients with rheumatoid arthritis (RA) (ICD-10 M05, M060, M068 or M069) with ≥2 b/tsDMARD dispensings, 2014–2019, followed until December 31, 2020 or death
- Participants
- 26,478 patients100,332 person-years
- Exposure
- TNF Inhibitors (TNFi) vs CTLA4-Ig vs Rituximab vs IL-6Ri vs JAK Inhibitors (JAKi)
- Outcome
- Nationwide b/tsDMARD treatment sequences after initiating a first b/tsDMARD
Methodological detailsnationwide, population-based, claims database (SNDS), Mean (SD) follow-up 3.8 years (±1.7 years)
- Nationwide
- Population-based
- Claims database (SNDS)
- Mean (SD) follow-up 3.8 years (±1.7 years)
Main finding
As reported in the abstract
First-line b/tsDMARD
Observational data: associations, not effects.
Further findings
Patient profiles by mode of action
- Age higher in CD20i and LT modulator patients; comorbidities more prevalent in CD20i treated patients
Original publication
Treatment sequences of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: A nationwide population-based study in France. Joint Bone Spine. Published 22 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →